Introduction and Context
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly become central therapies for type 2 diabetes and obesity because they improve glycemic control, reduce weight, and lower cardiovascular risk in selected patients. As their use has expanded, clinicians have begun asking a new question: could these drugs increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION?
NAION is the most common acute optic nerve ischemic event in adults over 50. It typically presents with sudden, painless visual loss in one eye, often noticed on awakening. Because the condition can cause permanent vision loss, even a small drug-associated risk is clinically important if it is real. Recent retrospective studies using electronic health records and claims databases have suggested a possible association between GLP-1 RAs, particularly semaglutide, and NAION. Other studies have not confirmed this link.
In response to this uncertainty, the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology issued a consensus statement to guide clinicians. The key message is cautious but not alarmist: the current evidence is limited, the absolute risk appears low, and treatment decisions should be individualized through shared decision-making rather than automatic discontinuation of therapy.
Why This Consensus Was Issued Now
The statement was prompted by a growing number of reports suggesting a possible signal between GLP-1 RA exposure and NAION. Several reasons made expert guidance necessary:
- GLP-1 RAs are now used by millions of patients, so even rare adverse events matter at a population level.
- Clinicians faced inconsistent findings across observational studies and no definitive prospective evidence.
- Patients with diabetes, obesity, hypertension, and sleep apnea—conditions common among GLP-1 RA users—already have baseline vascular risk factors that can confound the association.
- News coverage and social media discussion created anxiety among patients who were benefiting from these medications.
The consensus statement does not claim that GLP-1 RAs cause NAION. Instead, it explains that the evidence is insufficient to establish causality and that clinicians should interpret the data with care.
What the Evidence Shows
The strongest evidence to date comes from retrospective observational studies. These studies are useful for generating hypotheses, but they cannot fully control for confounding. Patients taking GLP-1 RAs often differ from nonusers in important ways: diabetes severity, weight, cardiovascular disease, kidney disease, and access to care may all influence both medication choice and vision outcomes.
Across the literature, findings are mixed:
- Some database studies reported a small increased relative risk of NAION among GLP-1 RA users.
- Other studies found no statistically significant association.
- Differences in outcome definitions, follow-up duration, comparator groups, and exposure ascertainment contribute to inconsistent results.
The consensus panel emphasized that many of the studies rely on electronic records or insurance claims, which may misclassify diagnoses or medication exposure. NAION is uncommon, so even a small number of coding errors can substantially affect results. In addition, the magnitude of any observed association has generally been small in absolute terms, meaning that the chance of an individual patient developing NAION remains low.
Core Expert Recommendations
The statement’s recommendations are practical rather than prescriptive. It does not recommend routine ophthalmic screening before starting a GLP-1 RA, and it does not advise automatic discontinuation in patients who are doing well on treatment. Instead, it focuses on individualized assessment.
1. Discuss risk in context
Clinicians should explain that the evidence for NAION risk is uncertain and based mainly on observational studies. Patients should understand that a possible association has been reported, but causation has not been proven.
2. Use shared decision-making
Whether to start, continue, or stop a GLP-1 RA should be decided jointly by the patient and the care team. This is especially important for patients who are gaining clear benefits from therapy, such as improved diabetes control, meaningful weight loss, or cardiovascular risk reduction.
3. Do not overreact to uncertainty
The consensus does not support routine avoidance of GLP-1 RAs solely because of a theoretical NAION risk. For many patients, the known metabolic and cardiovascular benefits may outweigh the uncertain and apparently low absolute ocular risk.
4. Be alert to visual symptoms
Patients should be advised to seek urgent evaluation for sudden painless vision loss, visual field defects, or a new altitudinal shadow. If NAION is suspected, prompt neuro-ophthalmic assessment is appropriate.
5. Coordinate care when vision loss occurs
If a patient develops NAION while receiving a GLP-1 RA, the treatment decision should be individualized. The expert statement does not mandate stopping the medication in every case. Clinicians should consider the timing of the event, the patient’s systemic risk profile, and the benefit the drug is providing.
What Has Changed Compared With Earlier Clinical Thinking
This consensus does not revise a prior formal NAION guideline; rather, it addresses a new safety question that emerged after widespread GLP-1 RA adoption. The major shift is not a new diagnostic algorithm for NAION, but a new framework for medication counseling.
| Issue | Older clinical stance | Current consensus position |
|---|---|---|
| Evidence base | No specific concern | Possible signal from retrospective studies, but inconsistent |
| Risk interpretation | Not applicable | Any absolute excess risk appears low |
| Medication management | No guidance | Individualized shared decision-making; no automatic discontinuation |
| Ophthalmic screening | No routine screening | Still no routine screening recommended solely for GLP-1 RA use |
| Patient counseling | General adverse effect counseling | Discuss uncertain NAION association and warning symptoms |
Special Clinical Considerations
Patients with diabetes
Patients with diabetes already have elevated vascular risk and may also have diabetic retinopathy or other eye disease. A suspected NAION signal should be interpreted in this broader context. Importantly, improved glucose control and weight reduction can lower overall morbidity, so stopping therapy lightly may do more harm than good.
Patients with obesity but no diabetes
For patients using GLP-1 RAs primarily for weight management, the balance of benefit versus risk may differ. The panel suggests that the decision should still be individualized, but clinicians may weigh the magnitude of weight-loss benefit, cardiovascular risk, and patient preferences carefully.
Patients with prior NAION or only one functional eye
These patients require especially careful counseling. The statement supports a case-by-case discussion rather than a blanket prohibition, but the threshold for involving a neuro-ophthalmologist should be low.
Patients with multiple vascular risk factors
Hypertension, hyperlipidemia, sleep apnea, smoking, and a crowded optic disc are established NAION risk factors. In such patients, attribution of NAION to a GLP-1 RA should be cautious because the drug may simply be present in a patient already at elevated baseline risk.
Expert Commentary and Controversies
The consensus panel highlights several unresolved issues.
First, there is no prospective randomized trial designed to detect NAION risk. Existing cardiovascular and weight-loss trials were not built for this rare ocular outcome, and most adverse-event reporting is not detailed enough to answer the question definitively.
Second, confounding by indication remains a major problem. Patients prescribed semaglutide may be sicker, more closely monitored, or more likely to have systemic conditions linked to NAION.
Third, the biological mechanism is uncertain. Some have speculated about rapid changes in body weight, blood pressure, or optic nerve perfusion, but no mechanism has been proven.
Fourth, expert opinion differs on how to act when a patient develops NAION during treatment. Some clinicians may prefer discontinuation out of caution, while others may prioritize the metabolic benefits of ongoing therapy. The consensus intentionally leaves room for individual judgment because the data do not support a one-size-fits-all rule.
Practical Implications for Clinicians
For everyday practice, the statement supports a balanced approach:
- Do not deny beneficial GLP-1 RA therapy solely because of an unconfirmed NAION signal.
- Inform patients about the uncertainty in a calm, factual way.
- Ask about sudden visual symptoms during follow-up.
- Promptly evaluate any suspected NAION, and coordinate with ophthalmology or neuro-ophthalmology.
- Reassess the overall risk-benefit profile if NAION occurs, rather than reflexively stopping treatment.
A brief counseling script may help: “There have been some reports of a possible link between GLP-1 medicines and a rare optic nerve condition, but the evidence is not definitive and the overall risk appears low. Because these medicines can provide major benefits, we should decide together whether continuing them makes sense for you.”
Illustrative Patient Scenario
Consider “Michael,” a 58-year-old man with type 2 diabetes, obesity, and hypertension who has lost 18 pounds on semaglutide and lowered his A1c substantially. He reads online about NAION and wants to stop the medication. Based on the consensus statement, his clinician should not assume that semaglutide is dangerous. Instead, they should review his vascular risk factors, explain that the NAION association is uncertain, and discuss the real benefits he is receiving. If Michael has no visual symptoms and values the drug’s benefits, continuing treatment with appropriate counseling is reasonable.
Bottom Line
The NAION-GLP-1 RA question is important, but current evidence does not justify panic or blanket treatment changes. The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology conclude that the reported association is based mainly on imperfect observational data, the absolute risk appears low, and patient-centered shared decision-making is the best approach. For clinicians, the key is to stay alert, communicate clearly, and avoid overinterpreting uncertain signals while preserving the benefits of effective metabolic therapy.
References
- DeParis SW, Oke I, Gaier ED, et al. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026 May 14. PMID: 42132708.
- PubMed record for the consensus statement: https://pubmed.ncbi.nlm.nih.gov/42132708/
- American Academy of Ophthalmology. Clinical guidance and policy resources on neuro-ophthalmic disease and medication safety. Accessed via AAO professional resources.
- North American Neuro-Ophthalmology Society. Expert statements and educational resources on NAION and optic nerve ischemia. Accessed via NANOS professional resources.
- Relevant observational literature on GLP-1 receptor agonists and NAION as discussed in the consensus statement, including retrospective database analyses and claims-based cohort studies.
